CURES database: health information technology system.
The implementation of this bill is expected to enhance the monitoring of prescription drugs in an effort to combat substance abuse and over-prescribing. By making comprehensive drug history information accessible to authorized healthcare providers, it empowers them to make informed decisions concerning patient prescriptions and reduces the risk of prescription drug misuse. Additionally, the stipulation that these health information technology systems comply with strict privacy and security regulations ensures that patient data remains confidential while still allowing necessary access to prescribed medication histories.
Assembly Bill 40, introduced by Santiago, amends Section 11165.1 of the Health and Safety Code to further regulate the Controlled Substance Utilization Review and Evaluation System (CURES). The bill mandates that by October 1, 2018, the California Department of Justice must provide healthcare practitioners and pharmacists access to an electronic history of controlled substances dispensed to patients under their care via this database, which is crucial for monitoring the prescription history of controlled substances classified under Schedule II, III, and IV. This move aims to mitigate issues surrounding drug abuse and ensure safer prescribing practices.
Overall, the sentiment surrounding AB 40 appears largely positive, especially among healthcare providers and advocates for responsible drug monitoring. Supporters emphasize the importance of having real-time access to patients' prescription histories to prevent drug misuse and improve the quality of care. However, concerns may arise regarding the operational implications for healthcare providers and the administration of the CURES database, including potential costs associated with system integration and compliance requirements.
Debate may center around the logistics of integrating various health information technology systems with the CURES database, particularly around compliance, fees for system maintenance, and the technical specifications required by the Department of Justice. There may be apprehensions regarding the effectiveness of these systems and how well they adhere to both state and federal patient privacy laws. While the bill is designed to enhance drug monitoring, the requirement for practitioners to submit applications for database access and potentially face consequences for non-compliance raises questions about the administrative burden on healthcare providers.